Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHER adaptive platform trial in monkeypox virus disease
PACTR202405860723287Phase 3Recruiting
- Sponsor
- PANTHER
- Start
- Sep 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of tecovirimat and brincidofovir in mpox, sponsored by PANTHER. Primary endpoint: Time to healing of all visible lesions. Started Sep 2024; status: recruiting.
02
Drugs
tecovirimatbrincidofovir
03
Conditions
mpox
Beyond the preview
Go deeper on PACTR202405860723287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405860723287.